



Mithra takes note of François Fornieri's indictment

Liege, Belgium, 28 avril 2021 – 21:15 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women's Health, announces having been informed of François Fornieri's indictment of alleged insider dealing charges following his audition held in Liège today by the federal judicial police.

Mithra reminds that since February 04, 2021, Mr. Fornieri no longer performs any management functions within the company and that the CEO function is now assumed by Mr Leon Van Rompay. Therefore, the indictment of Mr. Fornieri does not have any impact on the operational management of the company's activities. Following the recent approvals obtained for its contraceptive product Estelle[®], Mithra is more than ever focused on its ambitious objectives.

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen Estetrol in a wide range of applications in women health and beyond (Covid-19, neuroprotection...). Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.